Human protein tyrosine phosphatase inhibitors and methods of use

A method for regulating an angiogenesis related disease in a human, comprising administering to a human and effective amount of a compound having the formula:

• wherein R is a substituted or unsubstituted thiazolyl unit having the formula:
• R2 and R3 are each independently chosen from:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl;
• iii) substituted or unsubstituted phenyl;
• iv) substituted or unsubstituted heteroaryl;
• or
• R2 and R3 can be taken together to form a saturated or unsaturated ring having from 5 to 7 atoms;
• said substitutions are independently chosen from one or more C1-C6 linear, C3-C6 branched, or C1-C6 cyclic alkyl, —N(R11)2, —OR11, halogen, hydroxyl, or cyano units;
• each R11 is independently hydrogen, C1-C4 linear or C3-C4 branched alkyl;
• R4 is a unit chosen from:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl;
• iii) substituted or unsubstituted phenyl;
• or
• iv) substituted or unsubstituted heteroaryl;
• said substitutions are independently chosen from one or more C1-C6 linear, C3-C6 branched, or C1-C6 cyclic alkyl, —N(R11)2, —OR11, halogen, hydroxyl, or cyano units;
• each R11 is independently hydrogen, C1-C4 linear or C3-C4 branched alkyl;
• Z is a unit having the formula:
• R1 is chosen from:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl;
• iii) substituted or unsubstituted aryl;
• iv) substituted or unsubstituted heterocyclic rings;
• or
• v) substituted or unsubstituted heteroaryl rings;
• said substitutions are independently chosen from one or more halogen, C1-C6 linear, C3-C6 branched, or C3-C6 cyclic alkyl, —OR11, —CN, —N(R11)2, —CO2R11, —C(O)N(R11)2, —NR11C(O)R11, —NO2, —SO2R11, phenyl, benzyl;
• when R1 is substituted by phenyl or benzyl, said phenyl or benzyl can be substituted by halogen, C1-C3 alkyl, C1-C3 alkoxy, —CO2R11 and —NHCOR16;
• each R11 is independently hydrogen;
• substituted or unsubstituted C1-C4 linear, branched, cyclic alkyl, alkenyl, or alkynyl;
• substituted or unsubstituted phenyl or benzyl;
• or two R11 units can be taken together to form a ring comprising from 3-7 atoms;
• each R16 is independently hydrogen, methyl, or ethyl;
• L is a linking unit chosen from:
• i) —C(O)NH[C(R5aR5b)]w—;
• ii) —C(O)[C(R6aR6b)]x—;
• iii) —C(O)[C(R7aR7b)]yC(O)—;
• iv) —SO2[C(R8aR8b)]z—;
• R5a, R5b, R6a, R6b, R7a, R7b, R8a, and R8b are each independently:
• i) hydrogen;
• ii) substituted or unsubstituted C1-C4 linear or C3-C4 branched alkyl;
• iii) substituted or unsubstituted aryl;
• iv) substituted or unsubstituted heterocyclic rings;
• or
• v) substituted or unsubstituted heteroaryl rings;
• the index n is 0 or 1;
• the indices w and z are each independently from 0 to 4 and the indices x and y are each independently from 1 to 4;
• or a pharmaceutically acceptable salt thereof.